Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Next Previous
Trial Profile

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADEPT
  • Sponsors Abbott Laboratories

Most Recent Events

  • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
  • 03 Jan 2019 Results of a post-hoc anaysis assessing the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab or placebo and the impact of concomitant MTX, published in the Rheumatology
  • 08 Nov 2017 Results of post-hoc analysis (n=296) assessing the relationship between inhibition of radiographic progression and disease activity in Adalimumab and placebo treated patients presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top